AstraZeneca (AZ) has announced that it will be acquiring Fusion Pharmaceuticals and its next-generation radioconjugates (RCs) for approximately $2.4bn. The acquisition will give AZ access to Fusion’s pipeline of RCs, such as a potential treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The mid-stage candidate, FPI-2265, targets prostate-specific membrane antigen, a protein that is highly expressed in mCRPC. Source: PM Live 20/3/2024